06.05.2013 - French drug major Sanofi has licenced two ophthalmology antibody drug families to Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals, Inc. acquired exclusive rights to two families of novel antibodies invented at Regeneron and previously included in Regeneron's antibody collaboration with Sanofi. The antibodies target the PDGF receptors and ligands as well as the ANG2 (angiopoietin2) receptor and ligand and will be used both in ophthalmology. The programmes are currently in preclinical development stage.
With respect to PDGF antibodies, Regeneron will pay Sanofi US$10m upfront, up to US$40m in development milestone payments, and royalties on sales. With respect to ANG2 antibodies in ophthalmology, Regeneron will pay Sanofi US$10m upfront, a potential US$5m development milestone payment, and royalties on sales. Antibodies to ANG2 outside of ophthalmology will continue to be developed by Regeneron and Sanofi under their antibody collaboration agreement, including REGN910 (SAR 307746), an antibody to ANG2 that is currently in Phase 1 development in patients with advanced malignancies.
05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.
03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.